An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma (GLOW-FISH)
A Phase Ib/II First-in-human Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Marieke Kietselaer
- Phone Number: +31 88 972 7272
- Email: trialmanagement@prinsesmaximacentrum.nl
Study Locations
-
-
-
Utrecht, Netherlands
- Recruiting
- Prinses Maxima Centrum
-
Contact:
- Lideke van der Steeg
- Phone Number: +31 88 972 7272
- Email: a.f.w.vandersteeg@prinsesmaximacentrum.nl
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with the diagnosis of neuroblastoma as defined by histopathology (confirmed by the PMC Department of Pathology), who will be operated for NB as standard of care procedure
- Patients older than 1 year of age and not older than 18 years.
- Written informed consent from patients and/or from parents or legal guardians, according to local law and regulations
Exclusion Criteria:
- Previous treatment with Dinutuximab-beta, either alone or in combination with chemotherapy
- Pregnancy or positive pregnancy test (urine or serum) in females of childbearing potential. Pregnancy test must be performed within during the screening period and before the administration of the IMP.
- Breast feeding.
- Sexually active participants not willing to use highly effective contraceptive method (pearl index <1) as defined in CTFG HMA 2020 (Appendix I) during trial participation and until 6 months after end of protocol therapy.
- Patients that received prior treatment with chimeric antibodies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: anti-GD2-800CW
Participants will receive a single dose of anti-GD2-800CW 96 hours prior to surgery.
|
Participants will receive a single dose of anti-GD2-800CW 96 hours prior to surgery.
In phase Ib, using a 3+3 design, a dose escalation is performed to determine the RP2D.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To establish the recommended phase 2 dose (RP2D), based on efficacy and safety, of the anti-GD2-800CW fluorescent imaging agent in pediatric patients with neuroblastoma.
Time Frame: Through escalation phase completion, an average of 1 year.
|
Establishing the recommended phase 2 dose (RP2D), based on efficacy and safety, of the anti-GD2-800CW fluorescent imaging agent.
|
Through escalation phase completion, an average of 1 year.
|
|
To investigate safety of anti-GD2-800CW based on treatment related new AEs.
Time Frame: From IMP administration to 4 days after surgery
|
Registration of new AEs.
|
From IMP administration to 4 days after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the pharmacodynamic characteristics of an i.v. injection of anti-GD2-800CW.
Time Frame: From just before infusion to 4 days after surgery.
|
Assessment will be done by measuring Anti Drug Antibody formation using an ADA binding assay.
Blood samples will be taken at 8 time points.
|
From just before infusion to 4 days after surgery.
|
|
To assess the pharmacokinetic characteristics of an i.v. injection of anti-GD2-800CW.
Time Frame: From just before infusion to 4 days after surgery.
|
Assessment will be done by by measuring plasma levels Dinutuximab.
Dinutuximab levels will be measured over time to create a concentration-time profile per patient.
Blood samples will be taken at 8 time points.
|
From just before infusion to 4 days after surgery.
|
|
To correlate clinical imaging data with histopathology data to determine the accuracy for depicting GD-2 expressing vital tumor cells.
Time Frame: From start surgery to 3 weeks after surgery when the PA results are analyzed.
|
Pathologic status of removed fluorescent tissue and of removed fluorescent tissue will be compared to fluorescent status.
|
From start surgery to 3 weeks after surgery when the PA results are analyzed.
|
|
To assess the intra-operative usability of anti-GD2-800CW to distinguish tumor tissue from surrounding tissue on eyesight of the surgeons.
Time Frame: From start surgery to 3 weeks after surgery when the PA results are analyzed.
|
Score of ≥ 4.0 on a Likert scale of 1-5 based on the judgement of three surgeons.
They will grade the intra-operative visibility of the fluorescence and whether a clear distinction can be made on eyesight between tumor and surrounding tissue based on fluorescence.
|
From start surgery to 3 weeks after surgery when the PA results are analyzed.
|
|
To assess whether tumor load influences the fluorescence intensity.
Time Frame: From pre-operative scan to when PA results are analyzed, 3 weeks after surgery.
|
Tumor load will be examined in preoperative imaging with the tumor volume (cm3).
Additionally, we will denote the histopathological outcome with an estimation of vital tumor present after resection.
|
From pre-operative scan to when PA results are analyzed, 3 weeks after surgery.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-507596-22-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.